Annovis Bio, Inc. (ANVS) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]	1.5	2.2	1.6	2.4	1.9	3.1	3.0	1.5
General and administrative	1.5	2.2	1.6	2.4	1.9	3.1	3.0	1.5
Research and development	8.3	7.8	1.6	5.3	4.0	2.1	2.9	1.4
EBIT [+]	-9.8	-10.0	-3.2	-7.7	-6.0	-5.3	-5.9	-2.9
EBIT growth	63.4%	89.8%	-46.5%	168.9%	135.7%	62.7%	210.0%	77.9%
Interest income	0.2	0.2	0.1	0.1	0.0	0.0	0.0	0.0
Interest income	0.2	0.2	0.1	0.1	0.0	0.0	0.0	0.0
Pre-tax income	-9.5	-9.7	-3.1	-7.6	-5.9	-5.2	-5.9	-2.8
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-9.5	-9.7	-3.1	-7.6	-5.9	-5.2	-5.9	-2.8

Basic EPS [+]	($1.07)	($1.19)	($0.38)	($0.93)	($0.73)	($0.64)	($0.78)	($0.35)
Growth	46.5%	85.2%	-51.1%	165.5%	112.2%	38.8%	187.0%	140.1%
Diluted EPS [+]	($1.07)	($1.19)	($0.38)	($0.93)	($0.73)	($0.64)	($0.78)	($0.35)
Growth	46.5%	85.2%	-51.1%	165.5%	112.2%	38.8%	187.0%	140.1%

Shares outstanding (basic) [+]	9.0	8.2	8.2	8.2	8.2	8.2	7.6	8.1
Growth	9.6%	0.5%	7.0%	0.8%	10.8%	17.9%	20.9%	17.9%
Shares outstanding (diluted) [+]	9.0	8.2	8.2	8.2	8.2	8.2	7.6	8.1
Growth	9.6%	0.5%	7.0%	0.8%	10.8%	17.9%	20.9%	17.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.